Skip to content

Mahima Bansal

4 papers in the library · 47 citations · publishing 2023-2025

Papers

Sort Most recent Most cited

A Novel Stability Indicating High Performance Liquid Chromatography Method for Lysergic Acid Diethylamide Quantification: From Microdosing Applications to Broader Analytical Use.

Journal of Chromatographic Science November 15, 2025 Mahima Bansal, Estelle Miller, Rachael Sumner et al.

With the rising interest in therapeutic potential of microdosing lysergic acid diethylamide (LSD), accurate quantification and stability analysis are imperative for both scientific research and end-user safety. Currently, high throughput quantification of LSD in clinical microdosing formulations and community sourced microdosing samples remain a challenge due to the absence of fast analytical...

LSDDEP2: study protocol for a randomised, double-dummy, triple-blind, active placebo-controlled, parallel groups trial of LSD microdosing in patients with major depressive disorder.

Trials August 24, 2024 Dimitri Daldegan-Bueno, Carina Joy Donegan, Anna Forsyth et al. 14 citations

Major depressive disorder (MDD) poses a significant global health burden with available treatments limited by inconsistent efficacy and notable side effects. Classic psychedelics, including lysergic acid diethylamide (LSD), have garnered attention for their potential in treating psychiatric disorders. Microdosing, the repeated consumption of sub-hallucinogenic doses of psychedelics, has emerged...

PAM trial protocol: a randomised feasibility study of psychedelic microdosing-assisted meaning-centred psychotherapy in advanced stage cancer patients.

Pilot and Feasibility Studies February 12, 2024 Alesha Wells, A P Suresh Muthukumaraswamy, Eva Morunga et al. 10 citations

An advanced cancer diagnosis can be associated with a significant profile of distress. Psychedelic compounds have shown clinically significant effects in the treatment of psychological distress in patients with advanced-stage cancer. Given the challenges of delivering timely and effective intervention in the advanced cancer context, it is possible that an alternative, more pragmatic, approach...

An open-label pilot trial assessing tolerability and feasibility of LSD microdosing in patients with major depressive disorder (LSDDEP1).

Pilot and Feasibility Studies October 5, 2023 Carina Joy Donegan, Dimitri Daldegan-Bueno, Rachael Sumner et al. 23 citations

Globally, an estimated 260 million people suffer from depression [1], and there is a clear need for the development of new, alternative antidepressant therapies. In light of problems with the tolerability and efficacy of available treatments [2], a global trend is emerging for patients to self-treat depression with microdoses of psychedelic drugs such as lysergic acid diethylamide (LSD) and...